{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:29:39Z","timestamp":1771468179058,"version":"3.50.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Reactivation of hepatitis B virus (HBV) infection in patients treated for chronic hepatitis C (HCV) with direct-acting antiviral agents has emerged recently as an important safety issue; however, it has not been adequately studied in pediatric age groups. We aimed to evaluate this risk in adolescent patients infected with chronic HCV and positive for HBsAg and HBcAbs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and methods:<\/jats:title>\n            <jats:p>One hundred and fifteen adolescent patients from 12 to 17 years of age, infected with chronic HCV and positive for HBcAbs with or without HBsAg were included in this study. All patients were treated with 1 tablet daily of the fixed-dose combination sofosbuvir\/ledipasvir for 12 weeks. Patients were closely monitored throughout the study for virus load, liver functions, and other safety and efficacy outcome measures.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The sustained virologic response 12 (SVR12) rates were 96.7% (95% confidence interval: 88.6\u201399.1%) in HBsAg positive group and 98.2% (95% confidence interval: 90.4\u201399.7%) in HBsAg negative with HBcAbs positive group. Throughout the treatment period and the 12 weeks follow-up after treatment, there has been no single case in both HBsAg negative or positive that showed any manifestation of reactivation of hepatitis B, detected levels of HBV-DNA, or deterioration of liver functions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>No HBV reactivation was observed in adolescents treated for chronic HCV with direct-acting antiviral agents in our study, in both HBsAg positive or occult hepatitis B. Although results are reassuring, we still recommend close monitoring of liver functions to not miss even rare cases of such a potentially serious condition.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002894","type":"journal-article","created":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T16:00:59Z","timestamp":1600012859000},"page":"11-15","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of Chronic Hepatitis C in Adolescent Patients With Positive HBsAg or With Occult Hepatitis B: Is the Risk of Hepatitis B Reactivation Significant?"],"prefix":"10.1097","volume":"40","author":[{"given":"Hesham","family":"El-Khayat","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Endemic Medicine, Theodore Research Institute, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa","family":"Yakoot","sequence":"additional","affiliation":[{"name":"Green Clinic Research Centre, Alexandria, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mortada","family":"El-Shabrawi","sequence":"additional","affiliation":[{"name":"Pediatrics Hepatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasser","family":"Fouad","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Endemic Medicine, Minia University, Minia, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Attia","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Gastroenterology and Endemic Medicine, Beni-Suef University, Beni-Suef, Egypt."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enas M.","family":"Kamal","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Endemic Medicine, Minia University, Minia, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,9,7]]},"reference":[{"key":"R1-20250615","first-page":"8","article-title":"An update on the management of chronic hepatitis B and C infection.","volume":"9","author":"Carter","year":"2017","journal-title":"Clinical Pharmacist"},{"key":"R2-20250615","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/MPG.0b013e318258328d","article-title":"NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents.","volume":"54","author":"Mack","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R3-20250615","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ajg.2013.11.003","article-title":"Virologic and histologic characterisation of dual hepatitis B and C co-infection in Egyptian patients.","volume":"14","author":"Mekky","year":"2013","journal-title":"Arab J Gastroenterol"},{"key":"R4-20250615","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/hep.20944","article-title":"Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus\/hepatitis C virus-coinfected patients.","volume":"43","author":"Raimondo","year":"2006","journal-title":"Hepatology"},{"key":"R5-20250615","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s12072-009-9147-9","article-title":"Dual chronic hepatitis B virus and hepatitis C virus infection.","volume":"3","author":"Liu","year":"2009","journal-title":"Hepatol Int"},{"key":"R6-20250615","doi-asserted-by":"crossref","first-page":"e1984","DOI":"10.1002\/rmv.1984","article-title":"Hepatitis B virus (HBV) reactivation\u2014the potential role of direct-acting agents for hepatitis C virus (HCV).","volume":"28","author":"Blackard","year":"2018","journal-title":"Rev Med Virol"},{"key":"R7-20250615","doi-asserted-by":"crossref","first-page":"15578","DOI":"10.1128\/JVI.79.24.15578-15581.2005","article-title":"Hepatitis C virus (HCV) and hepatitis B virus (HBV) can coinfect the same hepatocyte in the liver of patients with chronic HCV and occult HBV infection.","volume":"79","author":"Rodr\u00edguez-I\u00f1igo","year":"2005","journal-title":"J Virol"},{"key":"R8-20250615","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1128\/jvi.69.2.1160-1171.1995","article-title":"Modulation of the trans-suppression activity of hepatitis C virus core protein by phosphorylation.","volume":"69","author":"Shih","year":"1995","journal-title":"J Virol"},{"key":"R9-20250615","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.1128\/jvi.67.10.5823-5832.1993","article-title":"Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells.","volume":"67","author":"Shih","year":"1993","journal-title":"J Virol"},{"key":"R10-20250615","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1074\/jbc.M204241200","article-title":"Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein.","volume":"278","author":"Chen","year":"2003","journal-title":"J Biol Chem"},{"key":"R11-20250615","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0168-8278(02)00296-9","article-title":"Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein.","volume":"37","author":"Sch\u00fcttler","year":"2002","journal-title":"J Hepatol"},{"key":"R12-20250615","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1006\/viro.2002.1701","article-title":"Hepatitis C virus NS2 protein inhibits gene expression from different cellular and viral promoters in hepatic and nonhepatic cell lines.","volume":"305","author":"Dumoulin","year":"2003","journal-title":"Virology"},{"key":"R13-20250615","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","article-title":"Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.","volume":"3","author":"M\u00fccke","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R14-20250615","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B.","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"R15-20250615","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/MPG.0000000000001968","article-title":"Dual sofosbuvir\/daclatasvir therapy in adolescent patients with chronic hepatitis C infection.","volume":"67","author":"Yakoot","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R16-20250615","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/jgh.12421","article-title":"Treatment of patients with dual hepatitis C virus and hepatitis B virus infection.","volume":"29","author":"Chun-Jen","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"R17-20250615","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/apt.14502","article-title":"The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience.","volume":"47","author":"El-Khayat","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R18-20250615","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/cid\/ciw507","article-title":"No evidence of reactivation of hepatitis B virus among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection.","volume":"63","author":"Sulkowski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R20-20250615","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/jvh.12784","article-title":"Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: Data from a national US cohort.","volume":"25","author":"Serper","year":"2018","journal-title":"J Viral Hepat"},{"key":"R21-20250615","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.3748\/wjg.v24.i28.3181","article-title":"Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: a systematic review and meta-analysis.","volume":"24","author":"Jiang","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R22-20250615","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcv.2016.02.026","article-title":"Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge.","volume":"78","author":"De Monte","year":"2016","journal-title":"J Clin Virol"},{"key":"R23-20250615","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12879-017-2287-y","article-title":"Reactivation of occult HBV infection in an HIV\/HCV Co-infected patient successfully treated with sofosbuvir\/ledipasvir: a case report and review of the literature.","volume":"17","author":"Fabbri","year":"2017","journal-title":"BMC Infect Dis"},{"key":"R24-20250615","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/cid\/civ474","article-title":"Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir.","volume":"61","author":"Collins","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R25-20250615","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13256-015-0630-8","article-title":"Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report.","volume":"9","author":"Ende","year":"2015","journal-title":"J Med Case Rep"},{"key":"R26-20250615","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/hepr.12578","article-title":"Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus\/hepatitis C virus co-infection.","volume":"46","author":"Takayama","year":"2016","journal-title":"Hepatol Res"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:05:35Z","timestamp":1750003535000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,7]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002894","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,7]]}}}